Loading...
Market
What will be Baird's rating for Lexeo Therapeutics by December 31, 2024?
3
Resolution / Starting Odds
Upgraded • 25%
Downgraded • 25%
Maintained • 25%
No rating • 25%
Baird's official research reports and ratings
Story
Lexeo Therapeutics Reports Positive Interim Data for LX2006 with 18.3% LVMI Reduction at 18 Months
Jul 15, 2024, 10:03 AM
Lexeo Therapeutics has announced positive interim Phase 1/2 clinical data for its gene therapy, LX2006, aimed at treating Friedreich Ataxia Cardiomyopathy. The data revealed a mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants who had elevated LVMI at baseline. Baird remains bullish on Lexeo, noting that levels approaching 20% would be a significant milestone. The Baird report suggests that the LX2006 update can provide further proof-of-concept. Despite some early data showing promise, there are concerns about the clarity of the results.
View original story
Similar markets
Increase by more than 20% • 25%
Increase by up to 20% • 25%
Decrease by up to 20% • 25%
Decrease by more than 20% • 25%
Less than $1B • 25%
$1B to $2B • 25%
$2B to $3B • 25%
More than $3B • 25%
Increase by 0-10% • 25%
Increase by 10-20% • 25%
Increase by more than 20% • 25%
Decrease or no change • 25%
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Remain about the same • 25%
Decrease • 25%
Less than 30% • 25%
30% to 49% • 25%
50% to 69% • 25%
70% or higher • 25%
Below $60 • 25%
$60-$70 • 25%
$70-$80 • 25%
Above $80 • 25%
Upgrade • 25%
Downgrade • 25%
No change • 25%
Rating withdrawn • 25%
Mostly positive • 25%
Mostly neutral • 25%
Mostly negative • 25%
Mixed • 25%
Outperforms sector • 25%
Performs similarly to sector • 25%
Underperforms sector • 25%
No significant change • 25%